help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by TAZI, A.
Right arrow Articles by HANCE, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by TAZI, A.
Right arrow Articles by HANCE, A. J.

Am. J. Respir. Crit. Care Med., Volume 157, Number 6, June 1998, 2007-2010

Relapsing Nodular Lesions in the Course of Adult Pulmonary Langerhans Cell Histiocytosis

ABDELLATIF TAZI, LAURENCE MONTCELLY, ANNE BERGERON, DOMINIQUE VALEYRE, JEAN-PAUL BATTESTI, and ALLEN J. HANCE

Service de Pneumologie, Hôpital Avicenne, Bobigny; and INSERM U 82, Faculté de Médecine Xavier Bichat, Paris, France

In most patients with pulmonary Langerhans cell histiocytosis (LCH), clinical and radiological abnormalities initially either stabilize or regress, often without treatment. Little information is available, however, concerning the subsequent evolution of disease in patients who initially follow a benign course. We describe four patients with biopsy-confirmed pulmonary LCH whose initial course was characterized by regression of parenchymal nodular lesions, but who subsequently developed one or more episodes of active disease 7 mo to 7.5 yr after their initial presentation. In each case, the subsequent episodes of active disease were characterized by the reappearance or marked increase in nodular radiographic abnormalities, whose presence was confirmed by high-resolution computed tomography (HRCT). Thus, initial regression of nodular lesions in pulmonary LCH does not preclude the reappearance of one or more episodes of active disease, and may have important consequences on the long-term prognosis of these patients.




This article has been cited by other articles:


Home page
 ChestHome page
B. J. Krajicek, J. H. Ryu, T. E. Hartman, V. J. Lowe, and R. Vassallo
Abnormal Fluorodeoxyglucose PET in Pulmonary Langerhans Cell Histiocytosis
Chest, June 1, 2009; 135(6): 1542 - 1549.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. Rajagopol and E. J. Mark
Case 32-2002 - A 58-Year-Old Man with Interstitial Pulmonary Disease
N. Engl. J. Med., October 17, 2002; 347(16): 1262 - 1268.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. SOLER, A. BERGERON, M. KAMBOUCHNER, O. GROUSSARD, M. BRAUNER, P. GRENIER, B. CRESTANI, H. MAL, A. TAZI, J. P. BATTESTI, et al.
Is High-Resolution Computed Tomography a Reliable Tool to Predict the Histopathological Activity of Pulmonary Langerhans Cell Histiocytosis?
Am. J. Respir. Crit. Care Med., July 1, 2000; 162(1): 264 - 270.
[Abstract] [Full Text]

Home page
 ThoraxHome page
A. Tazi, P. Soler, and A. J Hance
Rare diseases bullet 9: Adult pulmonary Langerhans' cell histiocytosis
Thorax, May 1, 2000; 55(5): 405 - 416.
[Full Text]

Home page
 ChestHome page
N. Mogulkoc, A. Veral, P. W. Bishop, U. Bayindir, C. A. C. Pickering, and J. J. Egan
Pulmonary Langerhans' Cell Histiocytosis: Radiologic Resolution Following Smoking Cessation
Chest, May 1, 1999; 115(5): 1452 - 1455.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1998 American Thoracic Society 		  ATS Par News